Clinical Trials Browser

Phase 1/2 × bemarituzumab × 1 year × Clear all

NCT05322577 2025-12-05

FORTITUDE-103

Phase 1/2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT07146919 2025-08-28

ANGELICA

Phase 1/2 Not yet recruiting

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms